The microalgae cell: vegetal factory for the production of biopharmaceuticals and vector for mucosal delivery.
Bioproduction of recombinant proteins (immunotoxins, fusion proteins, thermostable vaccines, glycoproteins,...)

Our mission, our innovation

We are bringing the production of therapeutic recombinant proteins to an industrial scale, in the first place of recombinant immunotoxins and fusion proteins, then of thermostable subunit vaccines, for applications in oncology, infectiology and vaccinology, using our own cell lines of transgenic microalgae by a perfectly controlled upstream process (bioreactors) and downstream processing.

Compared to current expression systems, our transgenic microalgae have the advantage of achieving better productivity and significantly reducing costs, but above all of accessing "difficult‑to‑express" proteins, and then being usable for mucosal administration.

To produce them, we only use tools validated by the biopharmaceutical industry.

DIFFERENTIATING from current expression systems (animal cells, yeasts, bacteria):

►NINKARAK^®: recombinant immunotoxins and fusion proteins ('recalcitrant', 'difficult‑to‑express' proteins) for short‑term applications in immuno‑oncology

►ALGAVAX^®: thermostable subunit vaccines, alongwith vegetal adjuvants

►ALGAPHARM^®: nasal, oral, pulmonary, topical delivery, innovative galenic pharmacology by controlled cellular fragmentation of microalgae

►ALGATHERAPEUTICS^®: in the longer run, with the aim to manufacture any other type of recombinant proteins in commercial quantities at a reduced cost.

IASO BIOPRODUCTION, a strategic vision

1. Eukaryotic microalgae

Highly productive, stable, multigenic microalgae cell lines

2. USP bioproduction

Industrial bioreactors in accordance with pharmaceutical practices

3. DSP bioproduction

Vectoring of the biodrugs by addressing the proteins in precise cellular compartments

4. Galenic pharmacology

Targeted delivery and controlled release from microalgae cells or fragments

5. Industrial platform

Industrial bioproduction of recombinant proteins, peptides and glycoproteins.

Biopharmaceuticals and microalgae

We use eukaryotic microalgae to produce therapeutic proteins:

www.erdyn.com/us/revolutionizing-biopharmaceuticals-the-rise-of-microalgae-as-protein-expression-platforms/

They are more efficient, less expensive and much more easily scaled‑up than transgenic higher plants.

Microalgae cells are also suitable for formulation in mucosal (nasal, oral, pulmonary) or topical delivery.

A concentrated expertise

Biological engineering

Genetic engineering of eukaryotic microalgae: We create our own cell lines capable of producing recombinant proteins targeted in specific compartments of the cell. We rely on the latest transformations techniques available: nuclear or chloroplastic, depending on each case.

Process engineering

Upstream and downstream process engineering, including production, optimization and process integration, harvesting, fractionation‑purification, in accordance with pharmaceutical industry practices and with regulations.

Pharmacological engineering

Pharmacological and galenic engineering in the designing and manufacturing of biodrugs vectored in microalgae cells for oral, mucosal, topical deliveries.

Engineering of industrial systems

Industrial and commercial development through systems engineering, stage‑gating methodology, quantitative risk analysis and management.

Science & Technology Council

A Scientific and Technological Council bringing together renowned experts from industry, biotechnology, pharmacology and molecular biology.

Our ambition innovation responsibility at the heart of medical innovation

Key figures

8 years

to full commercial application, producing kg of recombinant protein

50 %

the share that biodrugs will occupy in the global pharmacy market by 2030

2 hours

the time it takes for an archetypal microalgae to double its mass by phototrophic growth

10 €

the target cost to produce one gram of protein when vectored in microalgae cells

Contact us

Thank you, your message has been sent

IASO BIOPRODUCTION SAS
Head office: 3 chemin des Balmes, F‑69110 Sainte‑Foy‑les‑Lyon (France)
Establishment (project): SkyeHub Skyepharma, 55 rue du Montmurier, F‑38070 Saint‑Quentin‑Fallavier (suburb of Lyon, France)